货号:A107169
同义名:
S-(+)-Rolipram; (+)-Rolipram
(S)-(+)-Rolipram is a PDE4-inhibitor and an anti-inflammatory agent, less potent than its R-enantiomer.


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | PDE ↓ ↑ | PDE1 ↓ ↑ | PDE10A ↓ ↑ | PDE2 ↓ ↑ | PDE3 ↓ ↑ | PDE4 ↓ ↑ | PDE5 ↓ ↑ | PDE6 ↓ ↑ | 其他靶点 | 纯度 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Doxofylline | ✔ | 99+% | |||||||||||||||||
| Deltarasin |
+++
PDEδ , Kd: 38 nM |
95% | |||||||||||||||||
| 7-(2,3-Dihydroxypropyl)theophylline | ✔ | 98% | |||||||||||||||||
| Aminophylline |
+
PDE, IC50: 0.12 mM |
98+% | |||||||||||||||||
| Anagrelide HCl | ✔ | 99%+ | |||||||||||||||||
| Irsogladine | ✔ | AChR,mAChR | 99% | ||||||||||||||||
| PF-8380 |
+++
Autotaxin, IC50: 2.8 nM |
99%+ | |||||||||||||||||
| Dipyridamole | ✔ | 98% | |||||||||||||||||
| Balipodect |
++++
PDE10A, IC50: 0.3 nM |
99%+ | |||||||||||||||||
| Luteolin |
+
PDE1, Ki: 15.0 μM |
++
PDE2, Ki: 6.4 μM |
+
PDE3, Ki: 13.9 μM |
+
PDE4, Ki: 11.1 μM |
+
PDE5, Ki: 9.5 μM |
98% | |||||||||||||
| Milrinone |
++
PDE2, IC50: 5.2 μM |
++
PDE3, IC50: 2.1 μM |
ATPase | 99% | |||||||||||||||
| Pimobendan |
++
PDE3, IC50: 0.32 μM |
98% | |||||||||||||||||
| Cilostazol |
++
PDE3, IC50: 0.2 μM |
98% | |||||||||||||||||
| Fenspiride HCl |
+
PDE3, pIC50: 3.44 |
+
PDE4, pIC50: 4.16 |
99% (HPLC) | ||||||||||||||||
| (S)-(+)-Rolipram |
++
PDE4, IC50: 0.75 μM |
99% (HPLC) | |||||||||||||||||
| Apremilast |
+++
PDE4, IC50: 74 nM |
98% | |||||||||||||||||
| GSK256066 |
++++
PDE4B, IC50: 3.2 pM |
98+% | |||||||||||||||||
| Roflumilast |
++++
PDE4A4, IC50: 4.3 nM PDE4A1, IC50: 0.7 nM |
99% | |||||||||||||||||
| Rolipram |
+++
PDE4B, IC50: 130 nM |
99%+ | |||||||||||||||||
| Cilomilast |
+++
HPDE4, IC50: 120 nM LPDE4, IC50: 100 nM |
99% | |||||||||||||||||
| Avanafil |
++++
PDE5, IC50: 1 nM |
98% | |||||||||||||||||
| Vardenafil HCl Trihydrate |
++++
PDE5, IC50: 0.7 nM |
98% | |||||||||||||||||
| Tadalafil |
++++
PDE5, IC50: 1.8 nM |
98% | |||||||||||||||||
| Icariin |
++
PDE5, IC50: 0.432 μM |
98% | |||||||||||||||||
| Sildenafil | ✔ |
+++
PDE6, IC50: 33 nM |
98% | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | (S)-(+)-Rolipram, known as (+)-Rolipram, is a selective inhibitor of cyclic AMP (cAMP)-specific phosphodiesterase 4 (PDE4) with an IC50 of 1100 nM. It is effective in suppressing tumor necrosis factor-alpha (TNFα) production in human mononuclear cells[1].[2].[3]. |
| 体内研究 | Moreover, (+)-Rolipram (0.025-6.25 mg/kg; a single i.p. injection) reduces locomotor activity and induces head twitches in rats in a dose-dependent manner[2]. In further studies, (+)-Rolipram (0.06-25 mg/kg; a single i.p. injection) leads to a dose-related decrease in the rectal temperature of rats[2]. |
| 体外研究 | In laboratory settings, (+)-Rolipram (0.015-1000 μM; 20 h) has shown a dose-dependent ability to inhibit LPS-induced TNF production in human mononuclear cells, with an IC50 value of 550 nM[1]. |
| Concentration | Treated Time | Description | References | |
| mouse primordial germ cell-like cells (PGCLCs) | 10 μM | 7 days | Screening for chemicals that promote PGCLC proliferation, (S)-(+)-Rolipram was found to significantly promote PGCLC proliferation | EMBO J. 2017 Jul 3;36(13):1888-1907 |
| hippocampal slices | 0.1µM | 60 min | To investigate the rescuing effect of rolipram on LTP deficits caused by sleep deprivation, results showed that rolipram rescued the LTP deficits caused by sleep deprivation | Nature. 2009 Oct 22;461(7267):1122-5 |
| Adult feline left ventricular myocytes | 1 μM | To evaluate the effect of rolipram on ISO-mediated cAMP generation, results showed that rolipram significantly enhanced ISO-induced cAMP generation. | Circulation. 2014 Nov 11;130(20):1800-11 | |
| hippocampal slices | 1 μM | 20 min | To test the effect of rolipram on LTP deficits in hippocampal slices from APP/PS1 mice. Results showed that rolipram significantly ameliorated LTP deficits in APP/PS1 hippocampal slices, bringing LTP levels close to those of wild-type mice. | J Clin Invest. 2004 Dec;114(11):1624-34 |
| CHO cells | 0.1, 0.25, 0.5, 1.0, and 2.0 μM | 18 h | Rolipram overcame inhibition by MAG and myelin in a dose-dependent manner, completely blocking inhibition by MAG at 0.5 μM. | Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8786-90. |
| hippocampal slices | 0.03 μM, 0.3 μM, 3.0 μM | 45 min | Low concentrations of rolipram had no significant effect on basal cAMP levels, but significantly amplified the cAMP response to forskolin stimulation. | Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):15020-5 |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Sleep deprivation model | Intraperitoneal injection | 1 mg/kg | Injected immediately and 2.5 hours after training | To investigate the rescuing effect of rolipram on memory deficits caused by sleep deprivation, results showed that rolipram rescued the memory deficits caused by sleep deprivation | Nature. 2009 Oct 22;461(7267):1122-5 |
| Mice | APP/PS1 double-transgenic mice | Subcutaneous injection | 0.03 mg/kg | Acute administration: single dose 30 minutes before testing; Long-term administration: daily dose of 0.03 mg/kg for 3 weeks, followed by 6-8 weeks of withdrawal before testing. | To test the acute and long-term effects of rolipram on cognitive and synaptic functions in APP/PS1 mice. Acute administration significantly improved contextual fear conditioning deficits in APP/PS1 mice but had no significant effect on spatial working memory. Long-term administration significantly improved synaptic function (BST and LTP) and multiple cognitive functions (including associative learning, working memory, and reference memory) in APP/PS1 mice, with effects lasting at least 2 months after treatment cessation. | J Clin Invest. 2004 Dec;114(11):1624-34 |
| Mice | C57/Bl6 mice | Subcutaneous injection | 0.1 μmol/kg, 3.0 μmol/kg | 30 min before training | Low-dose rolipram significantly enhanced long-term memory (24-hr freezing), while high doses caused behavioral toxicity. | Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):15020-5 |
| Sprague-Dawley rats | Acute and subacute inflammation models | Intraperitoneal injection | 8 mg/kg | Single dose, observed for 60 min or 4 h | Rolipram significantly inhibited PAF or LPS-induced leukocyte rolling, adhesion, and emigration, and downregulated P- and E-selectin expression, but had no effect on ICAM-1 and VCAM-1 expression. | Br J Pharmacol. 2002 Apr;135(8):1872-81 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.63mL 0.73mL 0.36mL |
18.16mL 3.63mL 1.82mL |
36.32mL 7.26mL 3.63mL |
|
| CAS号 | 85416-73-5 |
| 分子式 | C16H21NO3 |
| 分子量 | 275.34 |
| SMILES Code | O=C1NC[C@@H](C1)C2=CC=C(C(OC3CCCC3)=C2)OC |
| MDL No. | MFCD03093861 |
| 别名 | S-(+)-Rolipram; (+)-Rolipram; (S)-Rolipram |
| 运输 | 蓝冰 |
| InChI Key | HJORMJIFDVBMOB-GFCCVEGCSA-N |
| Pubchem ID | 158758 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 105 mg/mL(381.34 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1